Overview

A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus

Status:
Recruiting

Trial end date:
2022-01-03

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and drug levels of BMS-986256 in participants with cutaneous lupus erythematosus.

Phase:

Phase 1

Details

Lead Sponsor:

Bristol-Myers Squibb